A Nano-pharmaceutical Platform for Creating Artificial Vaccines

Award Information
Agency: Department of Defense
Branch: Defense Health Program
Contract: W911NF-11-C-0267
Agency Tracking Number: O111-H01-3056
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2011
Solicitation Year: 2011
Solicitation Topic Code: OSD11-H01
Solicitation Number: 2011.1
Small Business Information
Parabon NanoLabs, Inc.
11260 Roger Bacon Drive, Suite 406, Reston, VA, -
DUNS: 828881305
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Steven Armentrout
 CEO
 (703) 689-9689
 steve@parabon.com
Business Contact
 Paula Gawthorp-Armentrout
Title: Corporate Secretary
Phone: (703) 689-9689
Email: paula@parabon.com
Research Institution
N/A
Abstract
In this project, Parabon NanoLabs (PNL) will demonstrate the feasibility of extending its Essemblix(tm) Drug Development Platform, a combination of computer-aided design (CAD) software and DNA nano-fabrication technology, to produce Essemblix-V, a platform for creating artificial vaccines from a predefined set of"building block molecules"assembled on DNA origami. Given an epitope for a potential biothreat agent, Essemblix-V will allow the production of artificial epitopes (hereafter"mimotopes") that can mimic the original epitope sufficiently to bind target antibodies with high affinity. Additionally, Essemblix-V will allow mimotopes to be arranged on origami in complex presentation patterns known to elicit rapid and potent immune response via T cell-independent activation. As a proof of concept, PNL will demonstrate the feasibility of (i) enhancing its existing inSequio(tm) CAD software to support the design of mimotopes with building block molecules; and (ii) modulating, through rational design, the charge distribution and hydrophobicity of specific mimotopes, since these attributes can affect conformation and stability. Prototype mimotopes will be created for /Borrelia burgdorferi/ and ricin toxin and their affinity to specific monoclonal antibodies will be demonstrated via ELISA assay. In Phase 2, artificial vaccines will be created for theses targets and evaluated in a murine model.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government